Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
3 'Strong Buy'-Rated Stocks to Buy Now on the Dip
These outstanding growth stocks are worth buying on the dip.
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in the...